Daiichi Sankyo and AstraZeneca’s supplemental Biologics License Application, or sBLA, for Enhertu has been accepted and granted priority review in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry (IHC) 3+) solid tumors who have received prior treatment or who have no satisfactory alternative treatment options.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
- AstraZeneca helped in competitive debate by Gilead’s EVOKE-01 miss, says BofA
- AstraZeneca initiated with an Overweight at Morgan Stanley
- AIM ImmunoTech enrolls first subject in Phase 1b/2 study of Ampligen
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits
- AstraZeneca announces commercial availability of Airsupra in U.S.